At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate Safety and Efficacy of Transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients With ALS
In Brief
A Phase 2 clinical trial evaluating Nurown MSC-NTF cells and Placebo for Amyotrophic Lateral Sclerosis (ALS). Completed, enrolled 48 participants across 3 sites.
Detailed Summary
This is a multi-center, randomized, double blind, placebo controlled study to evaluate the safety and efficacy of autologous (self) transplantation of Neurotrophic factors-secreting Mesenchymal Stromal Cells (MSC-NTF, NurOwn™) in patients with ALS . MSC-NTF cells are a novel cell-therapeutic approach which is expected to effectively deliver Neurotrophic factors, which are potent survival factors for neurons, directly to the site of damage.
Study Details
Timeline
Interventions
Single autologous MSC-NTF cells treatment by combined intramuscular and intrathecal administration
Excipient administration by combined intramuscular and intrathecal administration